Irhythm (IRTC) Stock
Wearable heart rhythm monitoring with cloud analytics. Here's the price, business snapshot, and what's worth knowing about Irhythm in August 2026.
iRhythm Technologies (IRTC) develops and operates the Zio ambulatory electrocardiogram (ECG) service: a wearable patch and cloud-based analytics that detect cardiac arrhythmias. Investors should know the business mixes device sales with recurring diagnostic and analytics revenue, giving exposure to both one-off volume and higher-margin service economics. Growth has been driven by broader use of remote cardiac monitoring, partnerships with providers, and improved AI-driven interpretation. Key risks include reimbursement pressure, regulatory scrutiny, competition from other wearables and implantable monitors, and dependence on physician adoption. Profitability has varied as the company invested in scaling operations and product development. For longer-term investors, the case rests on continued clinical adoption, stable reimbursement, and execution on margin expansion. This summary is general educational information, not personalised investment advice; values can rise and fall and past performance is not a reliable guide.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IRHYTHM Holdings' stock with a target price of $150.2, indicating strong potential growth.
Financial Health
IRHYTHM Holdings is generating steady revenue and cash flow, but profits are currently low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Wearable ECG Leader
Zio’s patch and analytics create a recognised monitoring service; recurring diagnostic revenue is a notable feature, though future returns depend on continued adoption and reimbursement.
Clinical Adoption Trends
Remote monitoring and guideline support could expand use across healthcare systems, yet slower uptake or reimbursement shifts would weigh on revenue.
Competition & Tech
AI-driven interpretation and product improvements are advantages, but competition from wearables and implantables presents execution and margin risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
